Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • BCAL Diagnostics has entered an exclusive licence agreement with ClearNote Health for the distribution of its pancreatic and ovarian cancer blood tests in Australia and New Zealand.

  • The agreement allows BCAL to integrate ClearNote’s Avantect® tests into its existing distribution network, with rollout scheduled for Q1 CY26.

  • The licence covers current and future tests based on ClearNote Health’s epigenomics platform.

BCAL Diagnostics Limited (ASX:BDX) saw its shares rise 7.69% to trade at AUD 0.07 during the session on 18 September 2025. The increase followed the announcement of a new agreement with ClearNote Health Inc., a US-based precision diagnostics company.

Exclusive Agreement with ClearNote Health

BCAL has secured rights to distribute and commercialise ClearNote Health’s Avantect® Pancreatic Cancer Test and Avantect® Ovarian Cancer Test in Australia and New Zealand. The arrangement also covers any future tests developed using ClearNote Health’s proprietary epigenomics testing platform.

The agreement is initially set for two years, commencing in Q1 CY26, with an option to extend for a further six years. BCAL intends to leverage its existing distribution partnerships to deliver these tests across its established medical networks.

Integration into BCAL’s Distribution Network

BCAL will incorporate the Avantect® tests into its current distribution channels, which already include collaborations with Cancer Care and Associates, a global pathology provider, and the Sydney Breast Clinic. The addition of ClearNote Health’s products enhances BCAL’s oncology portfolio, complementing its existing breast cancer testing program.

The integration creates opportunities to reach more healthcare providers and build new partnerships across the region. With an expanding diagnostic offering, BCAL aims to provide non-invasive, clinically validated testing options to medical practitioners in Australia and New Zealand.

About ClearNote Health

Founded in 2016 in California, ClearNote Health’s technology was developed at Stanford University by scientists in the Stephen Quake laboratory. Its platform combines artificial intelligence and bioinformatics to analyse differences between cancerous and healthy cells in blood samples.

The company’s Avantect® Pancreatic Cancer Test has demonstrated sensitivity of approximately 68% and specificity of 97% in peer-reviewed studies. Its Avantect® Ovarian Cancer Test has shown sensitivity above 78% and specificity above 94%. These results indicate the potential for earlier detection compared with conventional screening methods.

ClearNote Health currently distributes its diagnostic tests across 70 countries through licensed partners. It has processed more than 20,000 patient samples to refine its early detection platform, generating peer-reviewed evidence and real-world data from patients in the United States and Europe.